This is exactly why I think the license deal is key. If another household pharma name strikes a deal with cydy, people will come investigating this new company they've never heard of. Well if [big pharma name] thinks this is worth throwing there money at, it's not Kool aid medicine on the otc anymore. It clears up the legitimacy we think is here but has kept most skeptics and casual investors away. OTC is full of scams so I don't blame them.